Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.
Chen J-L. et al, (2025), Nat Commun, 16
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Dold C. et al, (2025), Science Translational Medicine, 17
Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease
FitzPatrick MEB. et al, (2025), Nature Immunology
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Ibarz-Pavon AB. et al, (2025), Vaccine, 56
Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial
Cooke GS. et al, (2025), The Lancet
Diagnostic Challenges in Detecting Rubella Viral RNA in Cases of Congenital Rubella Syndrome Using RT-PCR in the Era of Elimination.
Herini ES. et al, (2025), Pediatr Infect Dis J
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Milotay G. et al, (2025), Nature Medicine
Priorities for rapid and cost-effective vaccines to improve outbreak responses
Gilbert SC., (2025), PLOS Biology, 23, e3003114 - e3003114
A first report of the detection of Avipoxvirus genomic sequences in louse flies (Diptera: Hippoboscidae).
Wawman DC. et al, (2025), Parasitology, 1 - 26
Author Correction: Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein.
Kim YC. et al, (2025), NPJ vaccines, 10
Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure
Zhao L. et al, (2025), PLOS Pathogens, 21, e1012959 - e1012959
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.
Siegal EZ. et al, (2025), NPJ vaccines, 10
Workshop report: One Health challenges and knowledge gaps in the control of intracellular infections with a focus on tuberculosis and leishmaniasis
Miller M. et al, (2025), Vaccine, 53, 126929 - 126929
Quantifying potential immortal time bias in observational studies in acute severe infection
Yates TA. et al, (2025), Open Forum Infectious Diseases